{"nctId":"NCT02038179","briefTitle":"Center of Research Translation (CORT) Project 2","startDateStruct":{"date":"2014-07"},"conditions":["Pre-hypertension","JNC 7 Stage I Hypertension"],"count":99,"armGroups":[{"label":"Allopurinol, Then Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Allopurinol","Drug: Placebo"]},{"label":"Placebo, Then Allopurinol","type":"EXPERIMENTAL","interventionNames":["Drug: Allopurinol","Drug: Placebo"]}],"interventions":[{"name":"Allopurinol","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pre-hypertension or stage I hypertension, defined as the following after the mean of two clinic measurements:\n* Systolic blood pressure (SBP) ≥ 120 and \\<160 or;\n* Diastolic blood pressure (DBP) ≥ 80 and \\< 100\n* Serum urate ≥ 5.0 mg/dL for men or ≥ 4.0 mg/dL for women\n* Age 18-40\n\nExclusion Criteria:\n\n* Any current pharmacological treatment for hypertension, including diuretics (calcium channel blockers at stable doses were later allowed)\n* Estimated glomerular filtration rate \\< 60 mL/min/1.73m2\n* Current use of any urate-lowering therapy or statins\n* Prior diagnosis of gout or past use of urate-lowering therapy for gout\n* Prior diagnosis of diabetes\n* Pregnancy, or recent delivery or last trimester pregnancy loss more recent than 3 months\n* Active smokers\n* Immune-suppressed individuals including transplant recipients or current use of azathioprine.\n* Leucopenia with absolute white cell count \\< 3000 /mL, anemia with hemoglobin \\< 12 g/dL, or thrombocytopenia with platelet count \\< 150,000/mL\n* Individuals of Han Chinese or Thai descent with HLAB5801 genetic phenotype\n* Serious medical condition that at investigator's judgment precludes utilization of a fixed dose of allopurinol","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Systolic Blood Pressure (SBP)","description":"Compare systolic blood pressure (SBP) captured by wearing a 24 hour ambulatory blood pressure monitor during each phase of treatment (allopurinol 300 mg/day PO or placebo). Change in systolic blood pressure is calculated by comparing SBP at the end of each treatment phase to pre-treatment values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"10.0"},{"groupId":"OG001","value":"-1.06","spread":"8.94"}]}]}]},{"type":"PRIMARY","title":"Change in Flow-mediated Arterial Vasodilation","description":"Compare endothelial function as indexed by flow-mediated arterial vasodilation (FMD) within each phase of treatment (allopurinol 300 mg/day PO or placebo). Percent (%) change in FMD is calculated by comparing FMD (%) at the end of each treatment phase to pre-treatment values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"0.55"},{"groupId":"OG001","value":"-0.1","spread":"0.42"}]}]}]},{"type":"PRIMARY","title":"Change in Serum Levels of High Sensitivity C-reactive Protein","description":"Serum level of high sensitivity C-reactive protein will be reported as a change during treatment phase (allopurinol 300 mg/day PO or placebo). Change in serum level of C-reactive protein is calculated by comparing serum values at the end of each treatment phase to pre-treatment levels.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.39"},{"groupId":"OG001","value":"0.8","spread":"0.82"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":99},"commonTop":["Fatigue","Nausea","Diarrhea","Headache","Itch"]}}}